Fortis Healthcare Ltd – Hospitals, Diagnostics & Court Dramas: ₹8,091 Cr Sales, ₹920 Cr Profits, and a 78x P/E Stethoscope

1. At a Glance

Fortis Healthcare (FHL) started in 1996 and now runs 36 facilities with ~4,000 beds across India, Nepal, Dubai, and Sri Lanka. Add to that a diagnostics empire via Agilus Diagnostics (89.2% stake), making them not just hospital operators but also one of the largest lab test printers in the country.

Financially: ₹8,091 Cr sales, ₹920 Cr PAT, 21.5% OPM. Stock trades at a P/E of 77.9x, which is basically “premium room with jacuzzi” level compared to peers.

2. Introduction

Fortis is the hospital chain where you don’t just check your cholesterol but also check Supreme Court orders. Once upon a time, the Singh brothers ran it into debt + litigation; now IHH Healthcare (Malaysia-Singapore giant) owns 31.2% and calls the shots.

With Apollo and Max hogging headlines, Fortis tries to carve its niche in oncology, cardiac sciences, and international medical tourism – basically fixing your heart while charging your wallet.

3. Business Model – WTF Do They Even Do?

Hospitals (core): 27 multi- and super-specialty hospitals, ~4,700 beds, 6,850+ doctors.
Diagnostics (Agilus, formerly SRL): 405 labs, 4,126 touchpoints, ~₹333/test realisation.

Specialty mix (Q3FY25):

Cardiac sciences – 17.6%
Oncology – 14.2%
Neurosciences – 8.7%
Orthopedics – 8.5%
Others (GI, renal, OPD, etc.) – 51% combined

Payor mix: TPAs 36%, Cash 34%, Govt 21%, International patients 8%.
Digital revenue: ~30%.

Translation: one-third comes from “cash walk-ins,” one-third from insurance headaches, and one-third from the government + foreigners.

4. Financials Overview

Metric	Jun’25 Qtr	Mar’25 Qtr	YoY %	QoQ %
Revenue (₹ Cr)	2,167	2,007	+16.6%	+8.0%
EBITDA (₹ Cr)	491	435	+19.7%	+12.9%
PAT (₹ Cr)	267	188	+51.3%	+42.0%
EPS (₹)	3.45	2.44	—	—

Annual EPS: ~₹11.5 → CMP ₹950 = P/E 78x.
Even Apollo looks cheaper on this metric.

5. Valuation – Fair Value Range

P/E Method: EPS ₹11.5 × 40–55x = ₹460–₹635.
EV/EBITDA: EV ₹73,673 Cr ÷ EBITDA ₹1,736 Cr = 42x. Fair 20–25x → ₹400–₹600.
DCF (growth optimist): Assume 12–13% revenue CAGR, fair value ~₹700–₹800.

👉 Fair Range: ₹500–₹800. CMP ₹950 = priced like a luxury hospital suite.

6. What’s Cooking – News & Triggers

Expansion Drive

To Read Full 16 Point